| Literature DB >> 32655947 |
Silvia Guarguagli1,2, Ilaria Cazzoli1, Aleksander Kempny1, Michael A Gatzoulis1, Sabine Ernst1.
Abstract
INTRODUCTION: Transseptal puncture (TSP) is a routine access route in patients with left-sided ablation substrates and is performed safely on fluoroscopy (+/- echocardiographic guidance). We report on our experience using a radiofrequency (RF) needle in an unselected group of patients to demonstrate safety and usefulness of direct tip visualization on the 3D electroanatomical mapping (EAM) system with specific emphasis on total radiation exposure. METHODS ANDEntities:
Year: 2020 PMID: 32655947 PMCID: PMC7322610 DOI: 10.1155/2020/5420909
Source DB: PubMed Journal: Cardiol Res Pract ISSN: 2090-0597 Impact factor: 1.866
Figure 1Flowchart of the different patient groups. DAP: Dose Area Product, FT: fluoroscopy time, EAM: electroanatomical mapping, and CHD: congenital heart disease.
Figure 2Direct visualization (yellow circle) of the needle tip on the electroanatomical mapping system (Left Anterior Oblique Projection): needle tenting on the fossa ovalis (A) and in the left atrium (B). FAM of right atrium (RA) merged with the 3D reconstruction of a preacquired CT scan and two decapolar catheters in His and coronary sinus (CS) position. Ao: aorta.
Patient demographics overall.
| Median age (IQR) | Gender | Median BMI (IQR) | Arrhythmia type | Additional information | |
|---|---|---|---|---|---|
| Structurally normal heart | 64 (52–69) | 10F/13M | 27.9 (24.5–31.1) | AF = 21 pts AT = 2 pts | 12 pts with at least one previous TSP |
|
| |||||
| Dilated cardiomyopathy | 52 (44–63) | 3M | 26.3 (24.0–27.4) | VT = 1 pt AF = 2 pts | 1 pt with previous TSP |
|
| |||||
| Valvular heart disease | 36 | M | 30.9 | AF | Marfan syndrome, aortic root replacement + resuspension of aortic valve, MV and TV repair, and previous AF ablation |
|
| |||||
| Adult congenital heart disease | 58 (46–66) | 7F/8M | 25.5 (23.2–27.5) | AF = 8 pts AT = 6 pts | 9 pts with artificial septal closure (surgical or device); 9 pts with at least one previous TSP |
IQR: interquartile range, BMI: body mass index, M: male, F: female, VT: ventricular tachycardia, AT: atrial tachycardia, AF: atrial fibrillation, and MV: mitral valve.
Cases description for CHD conditions.
| Proc | Arrhythmia type | LA volume (ml) | TSP route (femoral/jugular) | Anatomy | Cardiac history and previous interventions |
|---|---|---|---|---|---|
| 1 | Paroxysmal AF | 81 | Femoral | AVSD | Partial AVSD + secundum ASD repair: VSD and ASD (fenestrated Dacron patch) closure + bidirectional Glenn. Hypoplastic RV |
|
| |||||
| 3 | Paroxysmal AF | 135 | Femoral | ASD + mitral | Mitral valvuloplasty, ASD closure with Amplatzer and previous AF ablation |
|
| |||||
| 5 | Paroxysmal AF | 90 | Femoral | ASD | Secundum ASD surgical repair, PM implanted, and previous AF ablation |
|
| |||||
| 7 | AT | 130 | Femoral | ASD | ASD repair; PM implanted |
|
| |||||
| 9 | AT | 95 | Femoral | VSD, coarctation, and bicuspid Ao | Bicuspid aortic valve AVR Mech + root, subaortic stenosis coarctation aorta repaired with redo, residual VSD, PM implanted, and 2 previous AT ablations |
|
| |||||
| 14 | Persistent AF | 190 | Femoral | AVSD + mitral | Common atrium with AVSD: repair of atrioventricular septal defect with Dacron patch, left atrioventricular valve repair, MV replacement with 27 mm bileaflet mechanical valve, and more than 60 DCCV in life |
|
| |||||
| 16 | AT | 110 | Femoral | CCTGA | CHB 29 mm St Jude TVR, VSD patch, PFO closure, LA cryoablation, CRT-D implanted, and previous AT ablation |
|
| |||||
| 17 | Persistent AF | 150 | Femoral | ASD | Secundum ASD surgical closed and previous AF ablation |
|
| |||||
| 19 | Persistent AF | 127 | Femoral | Cor triatriatum | No surgical intervention |
|
| |||||
| 28 + 41 | AT | 120 | Jugular | ASD + mitral | ASD and MV repair (parachute MV), recurrent endocarditis and finally metallic valve in atrial position and LAA in LV continuity, and bilaterally blocked femoral veins |
|
| |||||
| 30 | Paroxysmal AF | 152 | Femoral | AS | Congenital aortic stenosis: valvectomy aorta and myomectomy, aortic valve and ascending replacement, and previous AF ablation |
|
| |||||
| 33 | AT | 258 | Femoral | ASD | Secundum ASD closed and 3 previous AT/AF ablations |
|
| |||||
| 37 | Persistent AF | 168 | Femoral | TOF | Tetralogy Fallot repaired, previous AF and AFL ablations, and CRT-D implanted (PM dependent) |
|
| |||||
| 38 | Persistent AF | 209 | Femoral | VSD | VSD closure with Amplatzer and 3 previous AF ablations |
LA: left atrium, AVSD: atrioventricular septal defect, ASD: atrial septal defect, VSD: ventricular septal defect, RV: right ventricle, PM: pacemaker, AVR: aortic valve replacement, Mech: mechanical, Ao: aorta, CCTGA: congenitally corrected transposition of the great arteries, CHB: complete heart block, PFO: persistent foramen ovale, TVR: tricuspid valve replacement, TOF: tetralogy of Fallot, and LAA: left atrial appendage.
Figure 3Case-by-case fluoroscopy time (FT) and Dose Area Product (DAP). Boxplots group 1 versus group 2: a significant reduction is evident for both DAP and FT in group 2 (needle visualized on EAM) compared to group 1 (standard fluoroscopy guidance of the needle). (a) Dose Area Product in consecutive patients. (b) Fluoroscopy time in consecutive patients.